Sexual Function in Patients with Metastatic Midgut Carcinoid Tumours

被引:16
作者
van der Horst-Schrivers, Anouk N. A. [1 ,2 ]
van Ieperen, Ellen [2 ]
Wymenga, A. N. Machteld [6 ]
Boezen, H. Marike [3 ]
Weijmar-Schultz, Willibrord C. M. [4 ]
Kema, Ido P. [5 ]
Meijer, Wim G. [7 ]
de Herder, Wouter W. [8 ]
Willemse, Pax H. B. [2 ]
Links, Thera P. [1 ]
de Vries, Elisabeth G. E. [2 ]
机构
[1] Univ Groningen, Univ Med Ctr Groningen, Dept Endocrinol, NL-9713 AB Groningen, Netherlands
[2] Univ Med Ctr Groningen, Dept Med Oncol, NL-9713 AV Groningen, Netherlands
[3] Univ Med Ctr Groningen, Dept Epidemiol, NL-9713 AV Groningen, Netherlands
[4] Univ Med Ctr Groningen, Dept Gynaecol, NL-9713 AV Groningen, Netherlands
[5] Univ Med Ctr Groningen, Dept Pathol & Lab Med, NL-9713 AV Groningen, Netherlands
[6] Med Spectrum Twente, Dept Internal Med, Enschede, Netherlands
[7] W Friesch Gasthuis, Dept Internal Med, Hoorn, Netherlands
[8] Erasmus MC, Dept Endocrinol, Rotterdam, Netherlands
关键词
Sexual behaviour; Carcinoid tumour; Serotonin; Quality of life; QUALITY-OF-LIFE; SOLID-PHASE EXTRACTION; ANDROGEN DEFICIENCY; DYSFUNCTION; PREVALENCE; HEALTH; MEN; CHROMATOGRAPHY; TESTOSTERONE; DEPRESSION;
D O I
10.1159/000178754
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Sexual dysfunction is a poorly studied aspect of quality of life in patients with midgut carcinoid tumours. We investigated whether carcinoid patients experience sexual problems. Methods: Patients with metastatic midgut carcinoid tumours filled in a validated questionnaire for sexual dysfunction. The prevalence of dysfunction on the subscales arousal, erection, lubrication, orgasm and dyspareunia was compared to a Dutch reference population. Plasma concentration of gonadal hormones, tryptophan and urinary 5-hydroxyindolacetic acid concentrations were measured. Results: 43 patients were studied, 27 men and 16 women. Sexual dysfunction was present in 29.6% of men and 6.3% of women. The prevalence of sexual dysfunction on the different subscales did not differ from the reference population. Patients with a sexual dysfunction had, compared to those without a sexual dysfunction, a longer duration of disease, 95.3 months (range 5.4-314.5) versus 18.6 months (range 0.6-167.9) (p = 0.024), lower plasma tryptophan concentration (+/- SD) of 31.5 +/- 16.1 and 48.9 +/- 14.5 mu mol/l (p = 0.031), and more often used interferon-alpha, 50% of patients versus 10.5% of patients (p = 0.044). Conclusion: Patients with metastatic midgut carcinoid tumours do not experience sexual problems more often than a reference population. Male patients with sexual dysfunction are characterised by more long-standing disease and lower tryptophan concentration. Copyright (c) 2008 S. Karger AG, Basel
引用
收藏
页码:231 / 236
页数:6
相关论文
共 27 条
[21]   ESTIMATION OF PLASMA TESTOSTERONE WITHOUT EXTRACTION AND CHROMATOGRAPHY [J].
PRATT, JJ ;
WIEGMAN, T ;
LAPPOHN, RE ;
WOLDRING, MG .
CLINICA CHIMICA ACTA, 1975, 59 (03) :337-346
[22]   Patients with carcinoid syndrome exhibit symptoms of aggressive impulse dysregulation [J].
Russo, S ;
Boon, JC ;
Kema, IP ;
Willemse, PHB ;
den Boer, JA ;
Korf, J ;
de Vries, EGE .
PSYCHOSOMATIC MEDICINE, 2004, 66 (03) :422-425
[23]   The impact of hypogonadism and autonomic dysfunction on fatigue, emotional function, and sexual desire in male patients with advanced cancer - A pilot study [J].
Strasser, Florian ;
Palmer, J. Lynn ;
Schover, Leslie R. ;
Yusuf, S. Wamique ;
Pisters, Katherine ;
Vassilopoulou-Sellin, Rena ;
DeGracia, Beth ;
Willey, Jie S. ;
Bruera, Eduardo .
CANCER, 2006, 107 (12) :2949-2957
[24]   Psychiatric side effects of interferon therapy: prevalence, proposed mechanisms, and future directions [J].
Trask, PC ;
Esper, P ;
Riba, M ;
Redman, B .
JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (11) :2316-2326
[25]   CHROMATOGRAPHY OF URINARY INDOLE-DERIVATIVES [J].
VANHAARD, PMM ;
PAVEL, S .
JOURNAL OF CHROMATOGRAPHY-BIOMEDICAL APPLICATIONS, 1988, 429 :59-94
[26]  
Vroege JA, 1994, Vragenlijst voor het signaleren van Seksuele Dysfuncties (VSD), 5de versie Questionnaire for screening Sexual Dysfunctions (QSD)
[27]   Efficacy and safety of prolonged-release lanreotide in patients with gastrointestinal neuroendocrine tumors and hormone-related symptoms [J].
Wymenga, ANM ;
Eriksson, B ;
Salmela, PI ;
Jacobsen, MB ;
Van Cutsem, EJDG ;
Fiasse, RH ;
Välimäki, MJ ;
Renstrup, J ;
de Vries, EGE ;
Öberg, KE .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (04) :1111-1117